Data were presented as a late-breaking abstract at the 23rd Congress of the European Academy of Dermatology and Venereology (EADV) meeting in Amsterdam. The results of this study,
The contract renewal will extend over a five-year horizon. The company began working with the FDA in 2009. Under the terms of the contract, Symphony Health Solutions will
The privately-held Companies being acquired specialize in the development, manufacture and commercialization of complex generic and branded pharmaceutical products. The transaction will provide Impax with a highly-profitable and
In today’s competitive launch environment, biopharmaceutical leaders are utilizing these insights to help them to better understand potential pitfalls and ensure success at market entry. According to research
This data was presented at the European Association of Dermatology and Venereology (EADV) Congress, in Amsterdam, Netherlands. Secukinumab’s new mode of action stops interleukin-17A (IL-17A), which plays a
These results will be presented at the American Anesthesiology 2014 Annual Meeting in New Orleans, Louisiana. The investigator study was completed at the University of Medicine and Dentistry
Pursuant to the terms on the Collaboration Agreement, the Group will pay a technology transfer and drug development fee amounting to RMB 10 million to AMMS for the
Join Bürkert industry experts and Business Review Webinars, on 25 November to learn more about valuable insights to help your business. The first of a series of webinars
RDIM utilizes an orally disintegrating, controlled release, taste-masked pharmaceutical composition that can withstand compression forces associated with standard tableting technology, allowing for a drug to be incorporated into
Aciex is a private, US-based ophthalmic development pharmaceutical company with a strong near-term pipeline of therapeutics addressing major segments of the ophthalmic market, including allergy and inflammation. On
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.